Position of the Transparency Council – Lonsurf (trifluridine + tipiracil)

At its meeting on 28 October 2024, the Transparency Council adopted position No. 112/2024 on the evaluation of the drug Lonsurf (trifluridine + tipiracil) under drug program B.4 “Treatment of patients with colorectal cancer (ICD-10: C18-C20)”

Publication of the position >>